Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
09 nov. 2022 16h11 HE | Catalyst Pharmaceuticals, Inc.
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
07 nov. 2022 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Valux Digital Becomes a Trusted Member of Rare360
31 oct. 2022 10h00 HE | Valux Digital
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Valux Digital, a digital marketing and PR agency and a member of the Forbes Communications Council, is proud to announce it has been accepted into...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
25 oct. 2022 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
13 oct. 2022 16h05 HE | Travere Therapeutics, Inc.
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review...
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
11 oct. 2022 11h15 HE | Ambit Inc.
CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit's data-driven methodology for...
COMBINEDBrain Received the Global Genes 2022 Health Equity RARE Patient Impact Grant
29 sept. 2022 11h27 HE | COMBINEDBrain Inc
NASHVILLE, Tenn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- COMBINEDBrain (Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders), a non-profit organization of patient advocacy...
Biogen_Logo_Standard-rgb_R.jpg
The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
21 sept. 2022 17h15 HE | Biogen Inc.
Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data12-month data show earlier initiation of tofersen slowed...
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI-001 for the Treatment of Hemophagocytic Lymphohistiocytosis
06 sept. 2022 10h00 HE | Elixiron Immunotherapeutics
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
22 août 2022 07h00 HE | Travere Therapeutics, Inc.
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...